Astellas Pharma (Germany) Performance
| YPH Stock | EUR 13.48 0.20 1.46% |
On a scale of 0 to 100, Astellas Pharma holds a performance score of 15. The firm shows a Beta (market volatility) of 0.1, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Astellas Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Astellas Pharma is expected to be smaller as well. Please check Astellas Pharma's expected short fall, daily balance of power, and the relationship between the downside variance and kurtosis , to make a quick decision on whether Astellas Pharma's price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Astellas Pharma are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Astellas Pharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.0351 | Payout Ratio 1.0935 | Last Split Factor 5:1 | Forward Dividend Rate 0.48 | Ex Dividend Date 2026-03-30 |
1 | Prostate cancer pact, 88 percent hepatitis delta response, cash runway to 2028 at Vir - Stock Titan | 02/23/2026 |
Astellas |
Astellas Pharma Relative Risk vs. Return Landscape
If you would invest 1,067 in Astellas Pharma on November 29, 2025 and sell it today you would earn a total of 281.00 from holding Astellas Pharma or generate 26.34% return on investment over 90 days. Astellas Pharma is currently producing 0.4118% returns and takes up 2.0858% volatility of returns over 90 trading days. Put another way, 18% of traded stocks are less volatile than Astellas, and 92% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Astellas Pharma Target Price Odds to finish over Current Price
The tendency of Astellas Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 13.48 | 90 days | 13.48 | about 5.04 |
Based on a normal probability distribution, the odds of Astellas Pharma to move above the current price in 90 days from now is about 5.04 (This Astellas Pharma probability density function shows the probability of Astellas Stock to fall within a particular range of prices over 90 days) .
Astellas Pharma Price Density |
| Price |
Predictive Modules for Astellas Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Astellas Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Astellas Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Astellas Pharma is not an exception. The market had few large corrections towards the Astellas Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Astellas Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Astellas Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.37 | |
β | Beta against Dow Jones | 0.10 | |
σ | Overall volatility | 1.03 | |
Ir | Information ratio | 0.13 |
Astellas Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Astellas Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Astellas Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| About 57.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Prostate cancer pact, 88 percent hepatitis delta response, cash runway to 2028 at Vir - Stock Titan |
Astellas Pharma Fundamentals Growth
Astellas Stock prices reflect investors' perceptions of the future prospects and financial health of Astellas Pharma, and Astellas Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Astellas Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0738 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 20.54 B | ||||
| Shares Outstanding | 1.79 B | ||||
| Price To Earning | 29.54 X | ||||
| Price To Book | 1.89 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 1.91 T | ||||
| Gross Profit | 1.67 T | ||||
| EBITDA | 608.5 B | ||||
| Net Income | 50.75 B | ||||
| Cash And Equivalents | 305.99 B | ||||
| Cash Per Share | 165.15 X | ||||
| Total Debt | 266.53 B | ||||
| Book Value Per Share | 5.33 X | ||||
| Cash Flow From Operations | 194.51 B | ||||
| Earnings Per Share | 0.38 X | ||||
| Total Asset | 3.34 T | ||||
| Retained Earnings | 740.94 B | ||||
About Astellas Pharma Performance
By analyzing Astellas Pharma's fundamental ratios, stakeholders can gain valuable insights into Astellas Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Astellas Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Astellas Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15455 people.Things to note about Astellas Pharma performance evaluation
Checking the ongoing alerts about Astellas Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Astellas Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 57.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Prostate cancer pact, 88 percent hepatitis delta response, cash runway to 2028 at Vir - Stock Titan |
- Analyzing Astellas Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Astellas Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Astellas Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Astellas Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Astellas Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Astellas Pharma's stock. These opinions can provide insight into Astellas Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Astellas Stock analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |